Article Details
Retrieved on: 2024-08-21 19:24:57
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
... AstraZeneca's Imfinzi (durvalumab) + Imjudo (tremelimumab) and Bristol Myers Squibb's Opdivo (nivolumab) + Yervoy (ipilimumab). According to ...
Article found on: www.clinicaltrialsarena.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here